712 related articles for article (PubMed ID: 23352252)
1. Nucleotide-binding oligomerization domain containing 2: structure, function, and diseases.
Yao Q
Semin Arthritis Rheum; 2013 Aug; 43(1):125-30. PubMed ID: 23352252
[TBL] [Abstract][Full Text] [Related]
2. Morphologic and immunohistochemical characterization of granulomas in the nucleotide oligomerization domain 2-related disorders Blau syndrome and Crohn disease.
Janssen CE; Rose CD; De Hertogh G; Martin TM; Bader Meunier B; Cimaz R; Harjacek M; Quartier P; Ten Cate R; Thomee C; Desmet VJ; Fischer A; Roskams T; Wouters CH
J Allergy Clin Immunol; 2012 Apr; 129(4):1076-84. PubMed ID: 22464675
[TBL] [Abstract][Full Text] [Related]
3. Blau syndrome revisited.
Rose CD; Martin TM; Wouters CH
Curr Opin Rheumatol; 2011 Sep; 23(5):411-8. PubMed ID: 21788900
[TBL] [Abstract][Full Text] [Related]
4. Mutational analysis of human NOD1 and NOD2 NACHT domains reveals different modes of activation.
Zurek B; Proell M; Wagner RN; Schwarzenbacher R; Kufer TA
Innate Immun; 2012 Feb; 18(1):100-11. PubMed ID: 21310790
[TBL] [Abstract][Full Text] [Related]
5. Nod2-Nodosome in a Cell-Free System: Implications in Pathogenesis and Drug Discovery for Blau Syndrome and Early-Onset Sarcoidosis.
Iwasaki T; Kaneko N; Ito Y; Takeda H; Sawasaki T; Heike T; Migita K; Agematsu K; Kawakami A; Morikawa S; Mokuda S; Kurata M; Masumoto J
ScientificWorldJournal; 2016; 2016():2597376. PubMed ID: 27403452
[TBL] [Abstract][Full Text] [Related]
6. Nod1 and Nod2 in innate immunity and human inflammatory disorders.
Le Bourhis L; Benko S; Girardin SE
Biochem Soc Trans; 2007 Dec; 35(Pt 6):1479-84. PubMed ID: 18031249
[TBL] [Abstract][Full Text] [Related]
7. Blau syndrome-associated uveitis and the NOD2 gene.
Pillai P; Sobrin L
Semin Ophthalmol; 2013; 28(5-6):327-32. PubMed ID: 24010719
[TBL] [Abstract][Full Text] [Related]
8. Blau syndrome-associated Nod2 mutation alters expression of full-length NOD2 and limits responses to muramyl dipeptide in knock-in mice.
Dugan J; Griffiths E; Snow P; Rosenzweig H; Lee E; Brown B; Carr DW; Rose C; Rosenbaum J; Davey MP
J Immunol; 2015 Jan; 194(1):349-57. PubMed ID: 25429073
[TBL] [Abstract][Full Text] [Related]
9. Heterotypic interactions among NACHT domains: implications for regulation of innate immune responses.
Damiano JS; Oliveira V; Welsh K; Reed JC
Biochem J; 2004 Jul; 381(Pt 1):213-9. PubMed ID: 15107016
[TBL] [Abstract][Full Text] [Related]
10. Blau syndrome polymorphisms in NOD2 identify nucleotide hydrolysis and helical domain 1 as signalling regulators.
Parkhouse R; Boyle JP; Monie TP
FEBS Lett; 2014 Sep; 588(18):3382-9. PubMed ID: 25093298
[TBL] [Abstract][Full Text] [Related]
11. Blau syndrome NOD2 mutations result in loss of NOD2 cross-regulatory function.
Mao L; Dhar A; Meng G; Fuss I; Montgomery-Recht K; Yang Z; Xu Q; Kitani A; Strober W
Front Immunol; 2022; 13():988862. PubMed ID: 36189261
[TBL] [Abstract][Full Text] [Related]
12. Blau arteritis resembling Takayasu disease with a novel NOD2 mutation.
Khubchandani RP; Hasija R; Touitou I; Khemani C; Wouters CH; Rose CD
J Rheumatol; 2012 Sep; 39(9):1888-92. PubMed ID: 22859352
[TBL] [Abstract][Full Text] [Related]
13. [The present and the prospect of study on Blau syndrome/early-onset sarcoidosis].
Nakano M; Kambe N
Nihon Rinsho; 2013 Apr; 71(4):737-41. PubMed ID: 23678609
[TBL] [Abstract][Full Text] [Related]
14. Potential Benefits of TNF Targeting Therapy in Blau Syndrome, a NOD2-Associated Systemic Autoinflammatory Granulomatosis.
Matsuda T; Kambe N; Takimoto-Ito R; Ueki Y; Nakamizo S; Saito MK; Takei S; Kanazawa N
Front Immunol; 2022; 13():895765. PubMed ID: 35711422
[TBL] [Abstract][Full Text] [Related]
15. Structural insights into the MDP binding and CARD-CARD interaction in zebrafish (Danio rerio) NOD2: a molecular dynamics approach.
Maharana J; Patra MC; De BC; Sahoo BR; Behera BK; De S; Pradhan SK
J Mol Recognit; 2014 May; 27(5):260-75. PubMed ID: 24700593
[TBL] [Abstract][Full Text] [Related]
16. NOD2/CARD15 gene mutation identified in a Chinese family with Blau syndrome.
Xiang H; Zhang T; Chen M; Zhou X; Li Z; Yan N; Li S; Han Y; Gong Q; Liu X
Mol Vis; 2012; 18():617-23. PubMed ID: 22509093
[TBL] [Abstract][Full Text] [Related]
17. Clinical and genetic aspects of Blau syndrome: a 25-year follow-up of one family and a literature review.
Punzi L; Furlan A; Podswiadek M; Gava A; Valente M; De Marchi M; Peserico A
Autoimmun Rev; 2009 Jan; 8(3):228-32. PubMed ID: 18718560
[TBL] [Abstract][Full Text] [Related]
18. The cytosolic pattern-recognition receptor Nod2 and inflammatory granulomatous disorders.
Kambe N; Nishikomori R; Kanazawa N
J Dermatol Sci; 2005 Aug; 39(2):71-80. PubMed ID: 15927452
[TBL] [Abstract][Full Text] [Related]
19. Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis.
Okafuji I; Nishikomori R; Kanazawa N; Kambe N; Fujisawa A; Yamazaki S; Saito M; Yoshioka T; Kawai T; Sakai H; Tanizaki H; Heike T; Miyachi Y; Nakahata T
Arthritis Rheum; 2009 Jan; 60(1):242-50. PubMed ID: 19116920
[TBL] [Abstract][Full Text] [Related]
20. Insights into the molecular basis of the NOD2 signalling pathway.
Boyle JP; Parkhouse R; Monie TP
Open Biol; 2014 Dec; 4(12):. PubMed ID: 25520185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
